Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CleanTech Lithium confirms delay to planned ASX listing

(Sharecast News) - CleanTech Lithium said in an update on Wednesday that it now expected its Australian Securities Exchange (ASX) listing to launch in April and complete in May, later than initially planned. The AIM-traded company said it and its advisers believed waiting for a decision on entering direct negotiations for the special lithium operating contract (CEOL) for the Laguna Verde project, along with the completion of its pre-feasibility study (PFS), would strengthen its investment case in the Australian market.

As part of the ASX listing process, the firm said it would be required to include its audited financial results for 2024 in the prospectus.

Those financials were said to be well-advanced and were expected to be released by the end of March, ahead of the usual schedule, allowing the prospectus to be finalised soon after.

The pre-feasibility study remains on track for completion in April and will also be included in the prospectus.

Separately, the company announced that Tony Esplin, who was designated as CEO in November, had decided not to take up the role for personal reasons.

His appointment was conditional on the successful ASX listing, which was now expected in May.

Executive chairman Steve Kesler would continue as interim CEO while the board re-engaged with alternative candidates to lead CleanTech Lithium into its next phase of growth.

"We believe that pushing out the ASX listing to include the resolution allowing the company to enter direct negotiation with government on the CEOL and results from the pre-feasibility study will be taken positively by Australian investors," said executive chairman Steve Kesler.

"We regret that Tony has decided to withdraw from the proposed appointment as CEO, and we will start to re-engage with other high calibre candidates immediately."

At 1437 GMT, shares in CleanTech Lithium were down 5.88% at 12p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.